• home
• about us
  • the advantage
  • key facts
  • where we are
  • where we invest
  • management team
  • funds
• portfolio
  • companies
  • CEOs
• news
• investments
  • focus
    • prevention & nutraceuticals
    • medical foods OTC, Rx
    • enabling technologies
    • brands & channels
    • diagnostics
  • criteria
  • process
• your business
• careers
• contact us
  • the bahamas
  • united kingdom
  • switzerland
  • new zealand

portfolio

companies

CMP

CMP Therapeutics has developed a novel treatment for regulating and stimulating the immune system. The lead product is in Phase II clinical trials for allergic disorders. Other pipeline products have shown through stimulation of the immune system to protect against viruses and bacteria.

CMPT announces the injection of a €1.5million convertible loan from Inventages

2010-07-29

• CMPT's lead compound has Over the Counter (OTC) potential as a treatment for the common cold; clinical trials presently under way.
• CMPT has been supported solely by investments from Geneva based Inventages Venture Capital and New Zealand based BioPacificVentures since 2005.

Read the full article...

Neill Moray Mackenzie, CMP Therapeutics:
"Inventages has been extremely supportive of CMP Therapeutics since its inception."

www.cmptherapeutics.com

Back to portfolio ...